Nexvet to Discuss Pivotal Study Success of Lead Program and Product Pipeline at Bank of America Merrill Lynch 2015 Animal Health Summit

DUBLIN, Ireland, Dec. 8, 2015 (GLOBE NEWSWIRE) — Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the 2015 Bank of America Merrill Lynch Animal Health Summit in Boston on Wednesday, December 16th, at 8:55 AM ET.Dr. Mark Heffernan will discuss the Company’s recent success in its pivotal safety and efficacy study of NV-01, Nexvet’s monoclonal antibody (mAb) therapy in development for the control of pain associated with osteoarthritis in dogs. This study, the most advanced clinical study announced for a veterinary mAb in the area of pain management, met its primary endpoint as agreed under protocol concurrence with the FDA Center for Veterinary Medicine, and forms a substantial body of data, which Nexvet intends to use as the basis of planned submissions for marketing authorizations in both the U.S. and Europe.Dr. Heffernan will also discuss Nexvet’s strong pipeline of therapeutic veterinary biologics for companion animals. The Company’s pipeline is entirely composed of therapeutic biologics, which are notable for their significant advantages as a class over small molecule therapies, including safety, administration via injection, and an extended duration of action lasting weeks. Veterinarians have indicated in market surveys and at the Company’s recent Animal Health Symposium hosted on November 23rd, 2015 in New York City, that these factors are highly desirable for clinical practice and potentially game-changing for companion animal health.About Nexvet ( is a veterinary biologics developer focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet’s proprietary PETization™ platform is designed to rapidly design monoclonal antibodies (“mAbs”) that are recognized as “self” or “native” by an animal’s immune system, a property Nexvet refers to as “100% species-specificity.” Nexvet’s product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, which conducts drug discovery in Australia, clinical development in the United States and Europe and has acquired biomanufacturing capabilities in Ireland.Further information:

Candice Knoll
Blueprint Life Science Group
+1 415-375-3340 Ext. 4

David Salisbury
Berry & Company Public Relations
+1 212-253-8881